Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Ferring Nabs Japan Approval for Bladder Cancer Gene Therapy
Ferring Pharmaceuticals said on May 11 that it has won regulatory approval in Japan for Adstiladrin (nadofaragene firadenovec), an intravesical gene therapy for non-muscle invasive bladder cancer (NMIBC). The therapy was approved on May 8 for high-risk NMIBC with carcinoma…
To read the full story
Related Article
- Chuikyo OKs NHI Listing for Ferring’s Adstiladrin, Ishin’s Allostem Sheet
July 9, 2026
- Adstiladrin Expected to Ease Patient Burden in Bladder Cancer: Experts
June 17, 2026
- Chuikyo to Apply Drug Pricing Rules to Ferring’s Adstiladrin
May 14, 2026
- Ferring Gene Therapy, Fujifilm Cell Product Inch Closer to Approval
April 21, 2026
- Ferring, Nippon Kayaku to Co-Promote Bladder Cancer Gene Therapy
March 31, 2026
- Ferring Files for Japan Approval of Bladder Cancer Gene Therapy
September 8, 2025
BUSINESS
- Takeda CEO Says Orzeyful Could Redefine NT1 Standard of Care
July 31, 2026
- Pfizer Seeks Pediatric Expansion for Hympavzi in Japan
July 31, 2026
- Nippon Shinyaku Exercises Option for AB2 Bio’s Tadekinig Alfa in US
July 31, 2026
- Alfresa Takes Stake in Ember to Bolster Pharma Cold Chain in Japan
July 31, 2026
- Sanwa Kagaku Says Kumamoto Plant Remains Shut, Drug Supplies Stable
July 31, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…